Clinical Trials Browser

Phase 2 × Withdrawn × Gemcitabine × Clear all

NCT05415917 2026-05-07

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Phase 2 Withdrawn

Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

NCT06498518 2025-07-11

PRIMUS006

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03541486 2025-03-10

XACT-PANC-2

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT05861336 2024-12-27

OVERPASS

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02428764 2024-12-10

Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

Phase 2 Withdrawn

Lung Neoplasms

NCT06017297 2024-11-12

ESR-22-21719

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT04183062 2024-11-08

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Phase 2 Withdrawn

Bone Neoplasms, Sarcoma

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT04220008 2024-01-12

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Phase 2 Withdrawn

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Phase 2 Withdrawn

Gastrointestinal

Cholangiocarcinoma

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT02607423 2023-05-25

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04546828 2022-06-15

A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea

Phase 2 Withdrawn

Gastrointestinal

Cholangiocarcinoma

NCT05212025 2022-06-14

Adavosertib and Gemcitabine in Advanced Pancreatic

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT04796454 2022-06-01

PAMICC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

NCT02850874 2022-04-27

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms, Peritoneal Diseases

NCT03770299 2022-03-24

CheckMate 9TN

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05116800 2021-12-07

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Phase 2 Withdrawn

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04906876 2021-07-28

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Phase 2 Withdrawn

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04611776 2021-06-16

CATHAYA

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00226746 2020-09-18

Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT00020774 2020-07-31

SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT00728000 2019-11-25

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Phase 2 Withdrawn

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT02941601 2019-09-27

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT01524575 2019-09-25

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03392571 2019-05-07

Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

Phase 2 Withdrawn

Gastrointestinal

Resectable Pancreatic Cancer

NCT02405910 2017-11-06

Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Phase 2 Withdrawn

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00881387 2016-12-15

Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment

Phase 2 Withdrawn

Hodgkin Disease, Lymphoma

NCT01045941 2016-10-06

Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT00951444 2016-07-06

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00469976 2015-10-08

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00119314 2015-05-27

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Phase 2 Withdrawn

Neoplasms, Unknown Primary

NCT00458315 2015-05-08

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Phase 2 Withdrawn

Neoplasms, Unknown Primary

NCT00253526 2015-04-28

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT01336543 2014-12-18

Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00808145 2014-10-22

Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01639521 2014-01-29

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT01131039 2013-12-20

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00005591 2013-12-13

Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT01830322 2013-08-14

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Phase 2 Withdrawn

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT01834183 2013-06-19

Tivozanib + Gemcitabine in Metastatic RCC

Phase 2 Withdrawn

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00369954 2013-06-10

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Phase 2 Withdrawn

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00005614 2012-09-25

Management of Metastatic Breast Cancer in Frail Patients

Phase 2 Withdrawn

Breast Neoplasms

NCT00713687 2012-08-10

GemOx-PDT

Phase 2 Withdrawn

Gastrointestinal

Cholangiocarcinoma